BioMerieux Net Income 2017-2023 | BMXMF
BioMerieux annual/quarterly net income history and growth rate from 2017 to 2023. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
- BioMerieux net income for the quarter ending December 31, 2023 was $M, a NAN% increase year-over-year.
- BioMerieux net income for the twelve months ending December 31, 2023 was $0M, a NAN% increase year-over-year.
- BioMerieux annual net income for 2023 was $0.387B, a 18.8% decline from 2022.
- BioMerieux annual net income for 2022 was $0.477B, a 32.98% decline from 2021.
- BioMerieux annual net income for 2021 was $0.711B, a 53.95% increase from 2020.
| BioMerieux Annual Net Income (Millions of US $) |
|
|---|---|
| 2023 | $387 |
| 2022 | $477 |
| 2021 | $711 |
| 2020 | $462 |
| 2019 | $306 |
| 2018 | $303 |
| 2017 | $269 |
| 2016 | $198 |
| 2015 | $ |
| BioMerieux Quarterly Net Income (Millions of US $) |
|
|---|---|
| 2023-12-31 | |
| 2023-06-30 | |
| 2022-12-31 | |
| 2022-06-30 | |
| 2021-12-31 | |
| 2021-06-30 | |
| 2020-12-31 | |
| 2019-12-31 | |
| 2019-06-30 | |
| 2018-12-31 | |
| 2018-06-30 | |
| 2017-12-31 | |
| 2017-06-30 | |
| 2016-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $12.659B | $3.977B |
| bioM?rieux S.A. designs, develops, manufactures and markets systems in the field of vitro diagnostics. The company provides diagnostic solutions which determine the source of disease and contamination. It also offers solutions for managing infectious diseases, cancers and cardiovascular diseases in clinical applications. The company provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for the agri-food, cosmetics and pharmaceutical industries. bioM?rieux S.A. is based in Marcy L Etoile, France. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $84.995B | 10.55 |
| Cencora (COR) | United States | $43.734B | 16.44 |
| DiDi Global (DIDIY) | China | $22.941B | 0.00 |
| Natera (NTRA) | United States | $20.871B | 0.00 |
| ICON (ICLR) | Ireland | $16.879B | 15.03 |
| Viatris (VTRS) | United States | $14.478B | 4.46 |
| Avantor (AVTR) | United States | $14.307B | 21.45 |
| Revvity (RVTY) | United States | $13.453B | 23.37 |
| CochLear (CHEOY) | Australia | $11.807B | 0.00 |
| Solventum (SOLV) | United States | $11.540B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.417B | 29.35 |
| Doximity (DOCS) | United States | $10.302B | 60.64 |
| Charles River Laboratories (CRL) | United States | $9.314B | 18.00 |
| HealthEquity (HQY) | United States | $8.212B | 41.20 |
| Sonic Healthcare (SKHHY) | Australia | $8.208B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.322B | 29.43 |
| Amplifon S.p.A (AMFPF) | Italy | $5.864B | 29.89 |
| Sotera Health (SHC) | United States | $3.759B | 20.11 |
| Organon (OGN) | United States | $3.719B | 3.75 |
| BrightSpring Health Services (BTSG) | United States | $2.967B | 63.11 |
| Surgery Partners (SGRY) | United States | $2.493B | 28.42 |
| Concentras Parent (CON) | United States | $2.491B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.291B | 0.00 |
| GeneDx Holdings (WGS) | United States | $2.069B | 0.00 |
| Premier (PINC) | United States | $2.067B | 10.76 |
| PACS (PACS) | United States | $1.992B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $1.969B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.730B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.711B | 44.90 |
| Teladoc Health (TDOC) | United States | $1.544B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.224B | 11.98 |
| Progyny (PGNY) | United States | $1.208B | 24.47 |
| Embecta (EMBC) | United States | $1.161B | 8.12 |
| CareDx (CDNA) | United States | $1.102B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.090B | 0.00 | |
| AMN Healthcare Services Inc (AMN) | United States | $0.874B | 5.91 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
| Agilon Health (AGL) | United States | $0.775B | 0.00 |
| SBC Medicals (SBC) | United States | $0.649B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.492B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.478B | 0.00 |
| DocGo (DCGO) | United States | $0.444B | 16.73 |
| Sonida Senior Living (SNDA) | United States | $0.441B | 0.00 |
| Enhabit (EHAB) | United States | $0.387B | 33.48 |
| Sera Prognostics (SERA) | United States | $0.275B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.268B | 0.00 |
| LifeMD (LFMD) | United States | $0.212B | 0.00 |
| Biodesix (BDSX) | United States | $0.198B | 0.00 |
| Beauty Health (SKIN) | United States | $0.176B | 0.00 |
| Nutex Health (NUTX) | United States | $0.160B | 0.00 |
| ModivCare (MODV) | United States | $0.156B | 8.44 |
| MultiPlan (MPLN) | United States | $0.108B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.099B | 0.00 |
| So-Young (SY) | China | $0.093B | 15.69 |
| IceCure Medical (ICCM) | Israel | $0.052B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.050B | 0.00 |
| OncoCyte (OCX) | United States | $0.037B | 0.00 |
| NeueHealth (NEUE) | United States | $0.033B | 0.87 |
| Pheton Holdings (PTHL) | China | $0.027B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.023B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.023B | 0.00 |
| Oncology Institute (TOI) | United States | $0.016B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| KindlyMD (KDLY) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |
| Aclarion (ACON) | United States | $0.001B | 0.00 |